Servier India received approval recently from the CDSCO for the import, sale, and distribution of the medication
Servier India, a subsidiary of the leading French pharmaceutical Servier Group, announced the launch of Ivosidenib (Tibsovo), an oral targeted therapy approved in the management of cancer patients with Acute Myeloid Leukemia (AML) and Cholangiocarcinoma, with an isocitrate dehydrogenase-1 (IDH1) mutation. Servier India received approval recently from the Central Drugs Standard Control Organisation (CDSCO) for the import, sale, and distribution of the medication.
Aurélien Breton, Managing Director, Servier India, said, “Our focus is to advance oncology care by bringing innovative, precision medicines to patients who need them the most. By prioritising access and working to make treatment options affordable to patients, we are dedicated to bridging critical gaps in cancer care across the country. This launch is a significant step forward in our mission to support healthcare providers with targeted treatment options and ultimately improve survival outcomes and quality of life for patients throughout India.”
“This therapy represents a significant therapeutic option in the treatment of AML and Cholangiocarcinoma. For healthcare professionals, this precision therapy offers a new, effective option that can improve patient outcomes where traditional treatments have limited success. It highlights the benefits of targeted therapy and calibre of innovation in enhancing lives and advancing cancer care in India”, highlighted Dr Pranav Sopory, Medical and Patient Affairs Director, Servier India.
Pratima Tripathi, Commercial Director, Servier India, said, “Our foremost priority is to ensure that the therapy is accessible and affordable to patients across India. We are actively collaborating with healthcare providers, patient advocacy groups, and policymakers to remove barriers and facilitate timely access to this important therapy. Through these partnerships, we are committed to expanding treatment options and making a meaningful difference in the lives of patients.”
